Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function.

A relatively large body of evidence now appears to support the existence of the essential ingredients for novel intraovarian IGF-driven control mechanisms. Indeed, evidence presented in this communication is in keeping with the possibility that the granulosa cell may be the site of IGF production, reception, and action. Although the relevance of IGFs to ovarian cell types other than the granulosa cell is largely unknown, one cannot at the present time exclude the possibility of nongranulosa cell contributions to intraovarian IGF production, reception, and action. Indeed, preliminary affinity cross-linking studies (Adashi, Resnick, Svoboda, Van Wyk and D'Ercole; unpublished data) suggest the existence of type-I and type-II receptors in nongranulosa cell compartments. The above notwithstanding, IGFs of granulosa (and possibly circulatory) origins may interact with granulosa cell autoreceptors either independently or in synergy with other granulosa cell agonists. According to this view, IGFs may act in the autocrine mode to stimulate granulosa cell replication on the one hand and promote granulosa cell differentiation on the other. Although proliferation and terminal differentiation may prove mutually exclusive under some circumstances, coexistence of the two processes is being increasingly recognized. In this context, some studies of porcine granulosa cells support a dual role for IGFs in granulosa cell ontogeny. As such, the IGFs can be added to a growing list of growth factors known to modulate granulosa cell growth and function, including EGF, PDGF, and FGF. Our findings indicate that Sm-C/IGF-I synergizes with FSH in the induction of rat granulosa cell aromatase activity at nanomolar concentrations compatible with its granulosa cell receptor binding affinity (thus far studied only in porcine cells. A role for Sm-C/IGF-I in the regulation of this key granulosa cell function would be in keeping with the possibility that Sm-C/IGF-I may partake in the assertion and maintenance of dominance by the selected follicle(s) or in promoting juvenile and early follicular development. Moreover, the ability of Sm-C/IGF-I to potentiate this and other FSH-driven ovarian functions may also account, at least in part, for the puberty-promoting effect of growth hormone. This permissive action of growth hormone has been initially suggested by observation in growth hormone-deficient rats, mice (dwarf mutants, and humans (sporadic, hereditary or acquired growth hormone deficiency.(ABSTRACT TRUNCATED AT 400 WORDS)

Insulinlike growth factor action and production in adipocytes and endothelial cells from human adipose tissue.

Primary cultures of microvascular endothelial cells and isolated adipocytes were prepared from human omental adipose tissue to study the potentially overlapping roles of insulin and insulinlike growth factors (IGFs) in human adipose tissue. To determine whether adipocytes contain type I IGF receptors, binding experiments were carried out with 125I-labeled IGF-I. At 16 degrees C, saturation of specific binding to adipocytes was reached after 30 min and was 0.7% per 10(6) cells. At 37 degrees C, chloroquine produced an increase in cell-associated 125I-IGF-I, suggesting that IGF-I is internalized and degraded in a manner analogous to insulin. In competition experiments, IGF-I competed for binding more effectively than rat IGF-II or insulin. The concentrations of IGF-I, rat IGF-II, and insulin necessary to displace 50% of 125I-IGF-I binding were 2.5, 15, and 90 nM, respectively. In addition, a monoclonal antibody (alpha-IR3) that has been shown to block the type I IGF receptor was used in competition binding experiments. The antibody also inhibited binding of 125I-IGF-I to adipocytes. The biological effects of insulin and IGF-I were examined by studying adipocyte lipoprotein lipase (LPL). Insulin stimulated [14C]glucose incorporation into cellular lipid in a dose-dependent manner, with 50% effective concentration (EC50) of 0.3 nM. However, an increase in LPL activity was observed only at a high insulin concentration, with an EC50 of approximately 30 nM. In contrast, IGF-I stimulated a progressive increase in LPL, with an EC50 of 3.2 nM. In addition, alpha-IR3 blocked the stimulatory effect of IGF-I on adipocyte LPL.(ABSTRACT TRUNCATED AT 250 WORDS)

Interaction of the monoclonal antibodies alpha IR-1 and alpha IR-3 with insulin and somatomedin-C receptors.

alpha IR-3, a monoclonal antibody that interacts with the somatomedin-C receptor, inhibited the binding of somatomedin-C, but not of insulin, to human placental membranes and intact IM-9 cells. alpha IR-1, a monoclonal antibody that interacts with the insulin receptor, did not inhibit the binding of either hormone. Inhibition of somatomedin-C binding by alpha IR-3 was mainly due to a decrease in its affinity. 125I-Labeled alpha IR-3 bound specifically to placental membranes and intact IM-9 cells and was inhibited by concentrations of unlabeled alpha IR-3 that were lower than those required to inhibit somatomedin-C binding. [125I]alpha IR-3 binding was also inhibited by somatomedin-C and insulin, but only at very high concentrations. A410, a rabbit antiserum that reacts with both receptors for insulin and somatomedin-C, also inhibited labeled alpha IR-3 binding. alpha IR-I did not. These results help to define the epitopes with which these antibodies interact.

Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I.

Somatomedin-C (Sm-C) was purified from Cohn fraction IV of human plasma by previously published methods. Purity was established by SDS polyacrylamide electrophoresis followed by silver staining of the gel. Amino acid analysis of an acid hydrolysate revealed no significant discrepancies from the amino acid composition of insulin-like growth factor I (IGF-I). The first 24 residues beginning at the amino terminal glycine were identical to the corresponding residues in IGF-I. Tryptic and chymotryptic degradation followed by determination of the amino acid composition and sequence of the resultant peptides was used to complete the primary structure of Sm-C. The results of these studies document that Sm-C and IGF-I are identical peptides, thus supporting previous observations that Sm-C and IGF-I are qualitatively and quantitatively indistinguishable in radioligand and biological assay systems.

Characterization and regulation of a specific cell membrane receptor for somatomedin-C/insulin-like growth factor I in cultured rat granulosa cells.

The ovarian granulosa cell has recently been found to be a site of somatomedin-C/insulin-like growth factor I (Sm-C/IGF-I) production, reception, and action, thereby raising the prospect of a novel autocrine control mechanism concerned with granulosa cell ontogeny. It is the objective of the in vitro studies reported herein to explore the characteristics of the murine granulosa cell membrane Sm-C/IGF-I receptor and its regulation by gonadotropic, lactogenic, and beta 2-adrenergic signalling. Provision of FSH (150 ng/ml) to granulosa cells from immature rats cultured for 72 h under serum-free conditions resulted in a 3.1-fold increase over control values in specific cell-bound [125I]iodo-Sm-C/IGF-I. Binding to FSH-primed cells proved time, temperature, and pH dependent; optimal steady state conditions were achieved after an 8-h incubation at 15 C and a pH of 8.0. Although subject to regulation by the cellular density of plating, the binding of [125I]iodo-Sm-C/IGF-I to its receptor proved saturable (apparent Kd = 3.3 X 10(-9) M) as well as reversible; complete or partial tracer displacement was effected by competitive inhibition and dilution, respectively. Specificity studies revealed the competition for [125I]iodo-Sm-C/IGF-I binding to follow a relative rank order of potency of Sm-C/IGF-I much greater than multiplication-stimulating activity greater than insulin, but disclosed limited or no displacement by a series of chemically related and unrelated polypeptides. By Scatchard and Hill analysis, both control and FSH-treated cells displayed a single class of noninteracting binding sites; the FSH-enhanced binding represented largely increased binding capacity, rather than affinity. Significantly, up-regulation of granulosa cell Sm-C/IGF-I binding was not limited to FSH; qualitatively comparable increments in [125I]iodo-Sm-C/IGF-I binding were obtained after treatment with luteotropic, and beta 2-adrenergic (but not lactogenic) granulosa cell agonists. Taken together, these studies provide further evidence for the existence of high affinity, low capacity, specific cell membrane receptors for Sm-C/IGF-I in cultured rat granulosa cells. Our findings further indicate that the ability of FSH to enhance granulosa cell Sm-C/IGF-I binding largely reflects increased binding capacity rather than affinity and that this heterologous up-regulatory phenomenon may not be limited to FSH. As such, our observations of comparable up-regulation after luteotropic and beta 2-adrenergic (but not lactogenic) stimulation are in keeping with the view that cAMP may play an intermediary role in the regulation of granulosa cell type I IGF receptors.

In vivo regulation of granulosa cell somatomedin-C/insulin-like growth factor I receptors.

The characteristics and regulation of the murine granulosa cell type I insulin-like growth factor (IGF) receptor under in vivo conditions were studied. In vivo treatment of immature hypophysectomized diethylstilbestrol-treated rats with increasing doses (0.3-30 microgram/rat, twice daily) of FSH for 72 h resulted in dose-dependent increments in specific granulosa cell somatomedin-C (Sm-C)/IGF-I binding, peaking (5150 +/- 350 cpm/3 x 10(5) cells) at the 10 micrograms/rat (twice daily) dose level to yield a 2.6-fold increase relative to that in untreated controls. This FSH (10 micrograms/rat, twice daily) effect proved time dependent; the first significant (P less than 0.05) increase in binding (3670 +/- 150 cpm/3 x 10(5) cells) was noted after 48 h of treatment (1.6-fold increase). Significantly, little or no variation was observed for basal Sm-C/IGF-I binding over the course of the experiment, suggesting that this component of Sm-C/IGF-I receptor complement may be independent of the trophic influence(s) of the pituitary gland. Equilibrium competition studies carried out with granulosa cells derived from both control and FSH-treated rats revealed linear Scatchard plots consistent with a single class of noninteracting binding sites, a 2.8-fold increase in FSH-associated Sm-C/IGF-I-binding capacity, but not affinity (Kd control, 1.9 +/- 0.3 nM; kd FSH, 2.6 +/- 0.9 nM). Limited specificity studies of the FSH-induced receptor revealed related peptides to compete for Sm-C/IGF-I binding with a relative rank order of potency of Sm-C/IGF-I much greater than multiplication-stimulating activity greater than insulin, a pattern compatible with a type I IGF receptor. A series of other polypeptides, including porcine relaxin, porcine proinsulin, epidermal growth factor, basic fibroblast growth factor as well as transforming growth factor-alpha and -beta (TGF beta) were nonreactive. Significantly, the induced type I IGF receptor proved functionally coupled to granulosa cell proteoglycan biosynthesis. The ability of FSH (10 micrograms/rat, twice daily) to enhance granulosa cell Sm-C/IGF-I binding was significantly (P less than 0.05) up-regulated (1.53-fold amplification) by ovine GH (100 micrograms/rat, twice daily); a down-regulatory effect (64% inhibition) was observed for a potent GnRH agonist [( D-Ala6,Des-Gly10]GnRH ethyl amide; 25 micrograms/rat, twice daily). Once induced, the Sm-C/IGF-I receptor of the granulosa cell required the continued presence of either FSH or LH for its maintenance; the lactogenic receptor agonist PRL had no effect.(ABSTRACT TRUNCATED AT 400 WORDS)

A novel role for somatomedin-C in the cytodifferentiation of the ovarian granulosa cell.

The role of somatomedin-C (Sm-C) in the acquisition of granulosa cell progesterone biosynthesis was investigated in vitro in a primary culture of rat granulosa cells cultured for 72 h under serum-free conditions. Basal progesterone accumulation was negligible and remained unaffected by treatment with highly purified Sm-C (50 ng/ml). Whereas treatment with FSH (20 ng/ml) produced a 9-fold increase in progesterone accumulation, the concurrent application of increasing concentrations (0.3-50 ng/ml) of Sm-C brought about dose-dependent increments in the FSH-stimulated accumulation of progesterone with a median effective dose of 4.0 +/- (SE) 0.3 ng/ml and a maximal response 9.6-fold greater than that induced by FSH alone. A monoclonal antibody raised against Sm-C (sm 1.2) produced complete immunoneutralization of the synergistic interaction between FSH and Sm-C, supporting the specificity of the Sm-C effect and arguing against the possible involvement of copurified contaminant(s) in the preparation used. Treatment of granulosa cells with the highest dose of Sm-C tested (50 ng/ml), in the absence or presence of FSH, did not result in significant alterations in cell number, DNA content, plating efficiency or viability. Taken together, our findings indicate that Sm-C is capable of synergizing with FSH in the induction of granulosa cell progesterone biosynthesis. Significantly, this ability of Sm-C to augment differentiated phenotypic expression of the developing granulosa cell is distinct from its well established growth-promoting property and may thus represent a novel biologic effect of this polypeptide.

Somatomedin-C-mediated potentiation of follicle-stimulating hormone-induced aromatase activity of cultured rat granulosa cells.

We have recently observed that nanomolar concentrations of exogenously added somatomedin-C (Sm-C) are capable of synergizing with FSH in the induction of cultured rat granulosa cell progesterone biosynthesis and LH receptors without altering granulosa cell survival or replication. To further characterize the cytodifferentiative properties of Sm-C, we have undertaken to investigate whether the acquisition of granulosa cell aromatase activity is also subject to modulation by this intraovarian peptide. Granulosa cells from immature hypophysectomized diethylstilbestrol-treated rats were initially cultured for up to 3 days in an androstenedione-free medium, during which time aromatase activity was induced by FSH in the absence or presence of Sm-C (treatment interval). At the conclusion of this period, the cells were washed and reincubated for an additional 8-h test interval, during which time aromatase activity was estimated. Basal aromatase activity, as assessed by the conversion of unlabeled androstenedione (10(-7) M) to radioimmunoassayable estrogen, was negligible, remaining unaffected by treatment with highly purified Sm-C (50 ng/ml) alone. However, concurrent treatment with Sm-C (50 ng/ml) produced a 7.0-fold increase in the FSH (100 ng/ml; NIH FSH S14)-stimulated accumulation of estrogen. Similarly, Sm-C produced a 6.1-fold increase in FSH-induced aromatase activity, as assessed by the stereospecific generation of tritiated water from [1 beta-3H]androstenedione substrate. Sm-C-potentiated aromatase activity was dose and time dependent, with an apparent median effective dose of 5.0 +/- 1.9 (+/- SE) ng/ml and a minimal time requirement of 24 h or less, but was independent of the FSH dose employed. Although bovine insulin and multiplication-stimulating activity, like Sm-C, proved capable of augmenting aromatase activity (albeit at a substantially reduced potency), little or no effect was observed for either porcine or rat relaxin, a distantly related member of the insulin-like growth factor family. Examination of the apparent kinetic parameters of the aromatase enzyme revealed that the Sm-C-mediated potentiation of aromatase activity was due to enhancement of the apparent maximal reaction velocity, but not substrate affinity (Km = 2.8 X 10(-8) M). Our findings indicate that nanomolar concentrations of exogenously added Sm-C synergize with FSH in the enhancement of the maximal reaction velocity, but not Km, of granulosa cell aromatase in a dose- and time-dependent fashion.(ABSTRACT TRUNCATED AT 400 WORDS)

Characterization of a specific somatomedin-c receptor on isolated bovine growth plate chondrocytes.

The interaction of somatomedin (Sm) with growth plate chondrocytes (GPCs) is believed to be the primary stimulus of skeletal growth. Using techniques designed to disrupt as little as possible the phenotypic characteristics of GPCs, we have been able to obtain 3-4 x 10(8) viable cells from the major physes of one newborn calf. The availability of these cells plus essentially pure Sm-C/insulin-like growth factor I, the most GH-dependent Sm, has now made possible detailed studies of the interaction of this radiolabeled peptide with the GPC receptor and of the subsequent processing of this hormone by these cells. The enzymatic methods required to free GPCs from their matrix led to loss of receptors, followed by rapid receptor regeneration by de novo synthesis in suspension cultures. Binding of [125I]iodo-Sm-C to GPCs was time dependent and saturable, with optima at 15 C and pH 7.8. At 37 C, binding peaked at 90 min and declined thereafter. Multiplication-stimulating activity, insulin, and nerve growth factor were less potent than unlabeled Sm-C in competition with [125I]iodo-Sm-C for its receptor. Human GH, epidermal growth factor, and fibroblast growth factor failed to show competition even at 10(-6) M. Analysis of the fate of [125I]iodo-Sm-C bound to GPCs at 37 C provided evidence that this hormone is internalized and extruded from the cell in a partially degraded form. Scatchard analysis of [125I]iodo-Sm-C binding to GPCs and to chondrocytes isolated from articular cartilage revealed similar Ka values, but reproducibly 2-6 times more receptors on growth plate than on articular chondrocytes.

Somatomedin-C as an amplifier of follicle-stimulating hormone action: enhanced accumulation of adenosine 3',5'-monophosphate.

Somatomedin-C (Sm-C) has recently been found to amplify the FSH-mediated acquisition of granulosa cell progestin biosynthetic capacity, aromatase activity, and LH receptors, an effect distinct from its established replicative property. To further characterize the cellular mechanism(s) underlying the synergistic interaction of Sm-C with FSH, we have set out to evaluate the intermediary role of cAMP in this regard. Isolated granulosa cells from immature hypophysectomized diethylstilbestrol-treated rats were cultured for up to 3 days under serum-free conditions. The basal extracellular accumulation of cAMP remained unchanged in response to treatment with highly purified Sm-C (50 ng/ml). However, concurrent treatment with increasing concentrations (0.3-50 ng/ml) of Sm-C, produced dose- and time-dependent increments in the FSH-stimulated accumulation of cAMP, with an apparent median effective dose (ED50; mean +/- SE) of 5.1 +/- 0.6 ng/ml, a maximal response 8.8-fold greater than that induced by FSH alone, and a minimal time requirement of 1-2 days. Given increasing concentrations of FSH, treatment with a constant concentration (50 ng/ml) of Sm-C resulted in 1.7-, 5.8-, and 4.3-fold increases in cAMP accumulation for 10, 30, and 100 ng/ml FSH, respectively. The ability of Sm-C to augment FSH-stimulated cAMP accumulation was evident and, in fact, enhanced by ZK62711 (Rolipram; 3 X 10(-6) M)-induced blockade of cAMP-phosphodiesterase activity. Decreasing dilutions (1:64,000 to 1:1,000) of a monoclonal antibody raised against Sm-C (sm 1.2) produced progressive and complete immunoneutralization of the synergistic interaction of Sm-C with FSH, suggesting specificity of action. Taken together, these findings suggest that Sm-C, acting at nanomolar concentrations compatible with its granulosa cell receptor binding affinity (0.6-2.0 nM), is capable of amplifying FSH-stimulated cAMP accumulation in a time- and dose-dependent manner. These observations suggest that the synergistic action of Sm-C is exerted, at least in part, at a site(s) proximal to cAMP generation.